

**S2 Table. Overview of participants included in this analysis**

<b>NSAA</b>	<b>Study 101</b>	<b>Study 102</b>		<b>Both</b>
	Delandistrogene moxeparvovec N = 4	Assigned to received delandistrogene moxeparvovec in Part 1 (N = 20)	Assigned to receive placebo in Part 1 (N = 21) <sup>a</sup>	Total N = 45
<b>Number of remote assessments</b>	5	31	22	58
<b>Number of patients with remote assessments</b>	2	12	9	23
<b>Number of patients with remote and in-clinic assessments (within 2 weeks of one another)</b>	1	9	8	18
Number of patients with only one pair of remote and in-clinic assessments (within 2 weeks of one another)	0	8	7	15
Number of patients with more than one pair of remote and in-clinic assessments (within 2 weeks of one another)	1	1	1	3
<b>Comparable remote and in-clinic assessments</b>				
<b>Number of patients with comparable assessments</b>	1	9	8	18
<b>Number of instances (pairs of assessments)</b>	2	10	9	21

<sup>a</sup>These patients were to receive delandistrogene moxeparvovec in Part 2 of Study 102. As all remote assessment data are from Part 1 of Study 102, these patients did not receive delandistrogene moxeparvovec treatment.

NSAA, North Star Ambulatory Assessment.